{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T23:38:56Z","timestamp":1794699536228,"version":"4.9.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>Imatinib, a tyrosine kinase inhibitor has improved survival in pediatric patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. There are no formal drug interactions listed between methotrexate and tyrosine kinase inhibitors. Four pediatric patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia had delayed methotrexate clearance during their first cycle of high-dose methotrexate while receiving imatinib, resulting in acute kidney injury. For subsequent high-dose methotrexate cycles, imatinib was withheld resulting in decreased acute kidney injury, shorter time to methotrexate clearance, less toxicity, and shorter hospitalizations. For pediatric patients with acute lymphoblastic leukemia receiving imatinib, we recommend escalated supportive care measures including increased hyperhydration and leucovoruin frequency. For patients with toxicities secondary to delayed clearance or need for glucarpidase, we recommend holding imatinib with subsequent high-dose methotrexate courses.<\/jats:p>","DOI":"10.1097\/mph.0000000000001816","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T13:08:56Z","timestamp":1589288936000},"page":"e296-e300","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Concurrent Imatinib Dosing With High-dose Methotrexate Leads to Acute Kidney Injury and Delayed Methotrexate Clearance in Pediatric Patients With Philadelphia Chromosome-positive B-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.1097","volume":"43","author":[{"given":"Lauren","family":"Pommert","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology\/Blood and Marrow Transplantation, Medical College of Wisconsin and Children\u2019s Milwaukee, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Liberio","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology\/Blood and Marrow Transplantation, Medical College of Wisconsin and Children\u2019s Milwaukee, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wolfson Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tosha A.","family":"Egelund","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wolfson Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly J.","family":"Siver","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Katzenstein","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology\/Oncology, Nemours Children\u2019s Specialty Care and Wolfson Children\u2019s Hospital Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Burke","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology\/Blood and Marrow Transplantation, Medical College of Wisconsin and Children\u2019s Milwaukee, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"R1-20260901","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CAD.0b013e32835b8662","article-title":"Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia","volume":"24","author":"Csordas","year":"2013","journal-title":"Anticancer Drugs"},{"key":"R2-20260901","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Widemann","year":"2006","journal-title":"Oncologist"},{"key":"R3-20260901","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0091270007311571","article-title":"Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function","volume":"48","author":"Phillips","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R4-20260901","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","article-title":"Genome-wide study of methotrexate clearance replicates SLCO1B1","volume":"121","author":"Ramsey","year":"2013","journal-title":"Blood"},{"key":"R5-20260901","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.129668.111","article-title":"Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition","volume":"22","author":"Ramsey","year":"2012","journal-title":"Genome Res"},{"key":"R6-20260901","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2125.2008.03303.x","article-title":"Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy","volume":"67","author":"Suzuki","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R7-20260901","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00007691-200208000-00018","article-title":"Pharmacokinetic interaction between high-dose methotrexate and oxacillin","volume":"24","author":"Titier","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R8-20260901","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0022-3476(05)83351-7","article-title":"Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia","volume":"117","author":"Ferrazzini","year":"1990","journal-title":"J Pediatr"},{"key":"R9-20260901","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00278469","article-title":"The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis","volume":"42","author":"Tracy","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"R10-20260901","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children\u2019s Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"R11-20260901","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/asheducation-2011.1.361","article-title":"Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia","volume":"2011","author":"Hunger","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R12-20260901","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children\u2019s Oncology Group Trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"J Clin Oncol"},{"key":"R13-20260901","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.21218","article-title":"Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated with imatinib","volume":"83","author":"Van Hest","year":"2008","journal-title":"Am J Hematol"},{"key":"R14-20260901","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/jcpt.12298","article-title":"High methotrexate exposure and toxicity in children with t(9;22) positive acute lymphoblastic leukaemia treated with imatinib","volume":"40","author":"Loue","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"R15-20260901","doi-asserted-by":"crossref","first-page":"e27618","DOI":"10.1002\/pbc.27618","article-title":"Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib","volume":"66","author":"Ramsey","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R16-20260901","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/pbc.26395","article-title":"Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia","volume":"64","author":"Svahn","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R17-20260901","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/0008-5472.CAN-03-3344","article-title":"Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro","volume":"64","author":"Houghton","year":"2004","journal-title":"Cancer Res"},{"key":"R18-20260901","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1158\/0008-5472.CAN-03-4062","article-title":"Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions","volume":"64","author":"Breedveld","year":"2004","journal-title":"Cancer Res"},{"key":"R19-20260901","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R20-20260901","first-page":"503","article-title":"A phase I pharmacokinetic study of STI-571 in patients with advanced malignancies and varying degrees of renal dysfunction","volume":"22","author":"Remick","year":"2003","journal-title":"Proc Am Assoc Clin Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000001816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:03:45Z","timestamp":1788282225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000001816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001816","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]},"assertion":[{"value":"2019-10-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}